Unbuzzd Wellness Inc. Launches $5 Million Offering to Fuel Growth and IPO Ambitions

Unbuzzd Wellness Inc., under the umbrella of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM), has initiated a Regulation D 506(c) offering with the goal of raising up to $5 million. This financial endeavor is strategically planned to bolster the company's growth strategies and steer it closer to an initial public offering (IPO). A notable feature of this capital raise is the inclusion of an anti-dilution provision, ensuring Quantum BioPharma maintains its 25% ownership in Unbuzzd until the beverage company reaches a $1 billion valuation.

Unbuzzd is renowned for its flagship product, unbuzzd(TM), a beverage crafted to speed up alcohol metabolism, improve mental clarity, and reduce hangover effects. The company has appointed MZ Digital and Dealmaker to oversee the offering, which welcomes investments in both traditional and cryptocurrency forms. John Duffy, the CEO of Unbuzzd, highlighted that the raised capital will be pivotal in broadening the company's direct-to-consumer, distributor, and retail networks. Gerry David, Board Co-Chair, remarked on the significance of this collaboration in setting the stage for Unbuzzd's anticipated IPO.

Quantum BioPharma, the parent entity, is a biopharmaceutical company focused on pioneering treatments for neurodegenerative and metabolic conditions, including issues related to alcohol consumption. Its subsidiary, Lucid Psycheceuticals Inc., is leading the development of Lucid-MS, a patented solution targeting myelin damage in multiple sclerosis. Quantum BioPharma's investment in Unbuzzd reflects its dedication to advancing the biotech and wellness industries. For further insights into Quantum BioPharma's projects, visit https://ibn.fm/QNTM. To learn more about Unbuzzd and its innovative products, explore https://www.unbuzzd.com.